`Case No. IPR2015-00644
`Case No. IPR2015-00830
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________
`
`MYLAN PHARMACEUTICALS, INC.
`
`Petitioner
`
`v.
`
`YEDA RESEARCH AND DEVELOPMENT CO. LTD.
`
`Patent Owner
`____________________________
`
`Case No. IPR2015-00643 (8,232,250 B2)
`Case No. IPR2015-00644 (8,399,413 B2)
`Case No. IPR2015-00830 (8,969,302 B2)1
`____________________________
`
`MOTION FOR PRO HAC VICE ADMISSION
`OF SHANNON M. BLOODWORTH
`
`
`1 This Declaration of Shannon M. Bloodworth in Support of Motion for Pro Hac
`
`Vice Admission addresses all above referenced cases. The word-for-word identical
`
`paper is filed in each proceeding identified in the caption.
`
`
`
`I.
`
`Statement of Precise Relief Requested
`
`
`
`Mylan Pharmaceuticals Inc. (“Mylan”) hereby respectfully requests that the
`
`Patent Trial and Appeal Board (the “Board”) admit Shannon M. Bloodworth pro
`
`hac vice in this proceeding under 37 C.F.R. § 42.10(c).
`
`Patent Owner has stated it will not oppose this motion.
`
`II.
`
`Statement of Facts Showing Good Cause for the Board to Recognize
`Counsel Pro Hac Vice During the Proceeding
`Under 37 C.F.R. § 42.10(c), the Board may admit counsel pro hac vice for
`
`good cause, so long as lead counsel is a registered practitioner and subject to any
`
`other conditions the Board requires. Under Section 42.10(c), good cause includes
`
`when “counsel is an experienced litigating attorney and has an established
`
`familiarity with the subject matter at issue in the proceeding.” This motion
`
`satisfies the requirements of Section 42.10(c):
`
`1.
`
`Lead counsel, Jeffrey Guise, is a registered practitioner.
`
`2. Ms. Bloodworth is an experienced patent litigator and has an
`
`established familiarity with the subject matter at issue here, as shown in her
`
`accompanying October 8, 2015 Declaration (“Bloodworth Decl.”), attached hereto.
`
`That declaration shows that Ms. Bloodworth has been a litigator for 14 years. She
`
`is a member in good standing of the District of Columbia, Maryland, Virginia,
`
`Wisconsin, and is also admitted in several federal courts. She is also familiar with
`
`the subject matter of this case, including U.S. Patent No. 8,232,250, U.S. Patent
`
`
`
`- 1 -
`
`
`
`No. 8,399,413 and U.S. Patent No. 8,969,302, the prosecution history for each
`
`patent, the underlying technology, and the prior art cited by the petitioner in this
`
`matter. Bloodworth Decl. ¶¶ 8-9.
`
`3.
`
`In her declaration, Ms. Bloodworth also attests to each of the listed
`
`items required by the Order – Authorizing Motion for Pro Hac Vice Admission –
`
`37 C.F.R. § 42.10 in IPR2013-00639. See Bloodworth Decl. ¶¶ 2-13.
`
`III. Conclusion
`
`For the foregoing reasons, Mylan respectfully requests that the Board admit
`
`Shannon M. Bloodworth pro hac vice in this proceeding.
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`Reg. No. 52,354
`
`PERKINS COIE LLP
`700 13th Street, NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6204
`Facsimile: (202) 654-6211
`Email: bmwhite@perkinscoie.com
`
`Attorneys for Mylan Pharmaceuticals Inc.
`
`
`
`- 2 -
`
`
`
`Dated: October 8, 2015
`
`
`
`
`
`
`
`Case No. IPR2015-00643
`Case No. IPR2015-00644
`Case No. IPR2015-00830
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________
`
`MYLAN PHARMACEUTICALS INC.
`
`Petitioner
`
`v.
`
`YEDA RESEARCH AND DEVELOPMENT CO. LTD.
`
`Patent Owner
`____________________________
`
`Case No. IPR2015-00643 (8,232,250 B2)
`Case No. IPR2015-00644 (8,399,413 B2)
`Case No. IPR2015-00830 (8,969,302 B2)1
`____________________________
`
`DECLARATION OF SHANNON M. BLOODWORTH
`IN SUPPORT OF MOTION FOR PRO HAC VICE ADMISSION OF
`SHANNON M. BLOODWORTH
`
`
`
`1 This Declaration of Shannon M. Bloodworth in Support of Motion for Pro Hac
`
`Vice Admission addresses all above referenced cases. The word-for-word identical
`
`paper is filed in each proceeding identified in the caption.
`
`
`
`
`
`I, Shannon M. Bloodworth, declare as follows:
`
`1.
`
`2.
`
`I am a partner in the patent litigation group at Perkins Coie LLP.
`
`I am a member in good standing of the Bar of the States of Maryland
`
`and Wisconsin, the Commonwealth of Virginia and the District of Columbia. I am
`
`also admitted to practice before the United States Courts of Appeals for the Fourth
`
`Circuit, D.C. Circuit, Federal Circuit and the United States Supreme Court. I am
`
`admitted to practice before the United States District Courts for D.C. and
`
`Maryland, and the Supreme Courts of Virginia and Wisconsin.
`
`3. My Bar membership numbers are VA 46671, DC 474925 and WI
`
`1088470.
`
`4.
`
`I have been practicing law for almost 15 years, including litigating
`
`patent cases, specifically focused on pharmaceutical patent cases, for the last
`
`14 years.
`
`5. More generally, I have represented the Petitioner and/or and its
`
`various related entities in litigating significant pharmaceutical patent cases, such as
`
`the following infringement cases:
`
`•
`
`Teva Pharmaceuticals USA Inc., et al. v. Mylan Pharmaceuticals Inc.,
`
`et al., Civil Action No.1:09-cv-08824-WHP (U.S. District Court for
`
`the Southern District of New York);
`
`- 1 -
`
`
`
`•
`
`Teva Pharmaceuticals USA Inc., et al. v. Mylan Pharmaceuticals Inc.,
`
`et al., No. 10-cv-7246 (KBF) (U.S. District Court for the Southern
`
`District of New York);
`
`•
`
`Teva Pharmaceutical USA Inc., et al. v. Mylan Pharmaceutical Inc.,
`
`et al., Civil Action No. 1:14-cv-01278-GMS (U.S. District Court of
`
`District of Delaware);
`
`•
`
`Apotex, Inc. v. Daiichi Sankyo, Inc. et al., Civil Action No.
`
`1:15-cv-03695 (U.S. District Court for the Northern District of
`
`Illinois);
`
`•
`
`Janssen Biotech, Inc. et al. v. Mylan Pharmaceuticals Inc., et al.,
`
`Civil Action No. 2:15-cv-05909-KM-JBC (U.S. District Court for the
`
`District of New Jersey);
`
`•
`
`Astrazeneca Pharmaceuticals LP v. Agila Specialties Inc.et al., Civil
`
`Action No. 1:15-cv-06039-RMB-KMW (U.S. District Court for the
`
`District of New Jersey);
`
`•
`
`Astrazeneca AB et al. v. Mylan Laboratories Ltd., Civil Action No.
`
`3:12-cv-01378-MLC-TJB (U.S. District Court for the District of New
`
`Jersey);
`
`•
`
`The Medicines Co. v. Mylan Inc., Civil Action No. 1:11-cv-01285
`
`(U.S. District Court for the Northern District of Illinois);
`
`- 2 -
`
`
`
`•
`
`Teva Neuroscience, Inc. et al. v. Mylan Inc. et al., Civil Action No.
`
`2:10-cv-05078-CCC-JBC (U.S. District Court for the District of New
`
`Jersey); and
`
`•
`
`Novo Nordisk Inc. v. Mylan Pharmaceutical Inc., et al., Civil Action
`
`No. 3:09-cv-02445-FLW-DEA (United States District Court for the
`
`District of New Jersey).
`
`6.
`
`I have never been disbarred, sanctioned or cited for contempt by any
`
`court or administrative body. I am not currently suspended in any bar or by any
`
`court or administrative body.2
`
`7.
`
`I have never had a court deny my application for admission to
`
`practice.
`
`8.
`
`I am familiar with the subject matter of this proceeding. In addition to
`
`U.S. Patent Nos. 8,232,250 (“the ’250 patent”), 8,399,413 (“the ’413 patent”), and
`
`8,969,302 (“the ’302 patent”) and their prosecution histories, I am familiar with the
`
`technology at issue and with Copaxone, the pharmaceutical product for which the
`
`’250, ’413 and ’302 patents are listed by Teva as covering Copaxone in FDA’s
`
`
`2 In May 2004, during transition to a new law firm, my DC Bar dues were
`
`inadvertently not paid. As soon as I discover the non-payment, I immediately paid
`
`all outstanding dues and was reinstated. I have been a member in good standing
`
`ever since.
`
`- 3 -
`
`
`
`publication, Approved Drug Products with Therapeutic Equivalents Evaluations,
`
`commonly referred to as the “Orange Book.” I have been litigating issues
`
`surrounding Copaxone since 2009. I was lead counsel in a long-running case
`
`related to patents related to Copaxone 20 mg/mL product administered daily, Teva
`
`Pharmaceuticals USA Inc., et al. v. Mylan Pharmaceuticals Inc., et al., Civil
`
`Action No. 1:09-cv-08824 (S.D.N.Y.). See also Teva Pharmaceuticals USA, Inc.
`
`v. Sandoz, Inc., 723 F.3d 1363 (Fed. Cir. 2013); Teva Pharmaceuticals USA, Inc. v.
`
`Sandoz, Inc., 135 S. Ct. 831 (2015). I was also counsel in a litigation related to
`
`markers for measuring the molecular weight of glatiramer acetate, the active
`
`ingredient in Copaxone, Teva Pharmaceuticals USA Inc., et al. v. Mylan
`
`Pharmaceuticals Inc., et al., No. 10-cv-7246 (S.D.N.Y.). In addition, I am lead
`
`counsel in the pending cases related to Copaxone 40 mg/mL, Teva’s follow-on
`
`Copaxone product.
`
` Teva Pharmaceutical USA Inc., et al. v. Mylan
`
`Pharmaceutical Inc., et al., Civil Action No. 1:14-cv-01278 (D. Del.).
`
`9.
`
`In connection with my work on Copaxone litigations, I have become
`
`familiar with the prior art references that are the subject of this proceeding.
`
`10. Given my familiarity with the underlying facts and my litigation
`
`experience with the Federal Rules of Evidence, I have experience and expertise
`
`important to representing Mylan’s interests in this matter.
`
`- 4 -
`
`
`
`11.
`
`I have read and will comply with Office Patent Trial Practice guide
`
`and the Board's Rules of Practice for Trials, as set forth in Part 42 of 37 C.F.R.
`
`12.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Code of Professional Responsibility set forth in 37 C.F.R.§§ 11.101 et. seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`13.
`
`I have not previously applied for admission pro hac vice before the
`
`United States Patent and Trademark Office.
`
`14.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true; and further that these statements are made with the knowledge
`
`that willful false statements and the like are punishable by fine, imprisonment, or
`
`both, under Section 1001 of Title 18 of the United States Code.
`
`/s/ Shannon M. Bloodworth
`Shannon M. Bloodworth
`
`
`
`Dated: October 8, 2015
`
`
`
`
`- 5 -
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing:
`
`1. MOTION FOR PRO HAC VICE ADMISSION OF SHANNON M.
`BLOODWORTH, and
`
`2.
`
`DECLARATION OF SHANNON M. BLOODWORTH IN SUPPORT OF
`MOTION FOR PRO HAC VICE ADMISSION OF SHANNON M.
`BLOODWORTH
`
`was served electronically via email as follows:
`
`Patent Owners:
`
`Elizabeth Holland
`Goodwin Procter LLP
`eholland@goodwinprocter.com
`
`William James
`Goodwin Procter LLP
`wjames@goodwinprocter.com
`
`Eleanor Yost
`Goodwin Procter LLP
`eyost@goodwinprocter.com
`
`
`Dated: October 8, 2015
`
`
`
`
`
`
`
`/Brandon M. White/
`Brandon M. White
`
`Attorney for Mylan Pharmaceuticals Inc.